CO2022002493A2 - Nanoemulsion de ácido 18p-glicirretínico - Google Patents

Nanoemulsion de ácido 18p-glicirretínico

Info

Publication number
CO2022002493A2
CO2022002493A2 CONC2022/0002493A CO2022002493A CO2022002493A2 CO 2022002493 A2 CO2022002493 A2 CO 2022002493A2 CO 2022002493 A CO2022002493 A CO 2022002493A CO 2022002493 A2 CO2022002493 A2 CO 2022002493A2
Authority
CO
Colombia
Prior art keywords
glycyrrhetinic acid
formulation
nanoemulsion
treatment
acid nanoemulsion
Prior art date
Application number
CONC2022/0002493A
Other languages
English (en)
Inventor
Hernández Ulises Zendejas
Original Assignee
Atso Corp Affairs S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atso Corp Affairs S A De C V filed Critical Atso Corp Affairs S A De C V
Publication of CO2022002493A2 publication Critical patent/CO2022002493A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación farmacéutica que comprende ácidβ 18 -glicirretínico, siendo dicha formulación una nanoemulsión con el objeto de potenciar la biodisponibilidad del principio activo, método de preparación de la formulación y su uso en el tratamiento de infecciones causadas por el virus del papiloma humano. Está pensada para la aplicación en la zona vaginal y del cérvix para el tratamiento de infecciones causadas por el virus del papiloma humano, como el cáncer cervicouterino.
CONC2022/0002493A 2019-08-08 2022-03-01 Nanoemulsion de ácido 18p-glicirretínico CO2022002493A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2019009482A MX2019009482A (es) 2019-08-08 2019-08-08 FORMAS FARMACEUTICAS DEL ACIDO 18ß-GLICIRRETINICO.
PCT/MX2020/050025 WO2021025550A1 (es) 2019-08-08 2020-08-07 Nanoemulsion de ácido 18p-glicirretínico

Publications (1)

Publication Number Publication Date
CO2022002493A2 true CO2022002493A2 (es) 2022-04-29

Family

ID=74503526

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002493A CO2022002493A2 (es) 2019-08-08 2022-03-01 Nanoemulsion de ácido 18p-glicirretínico

Country Status (9)

Country Link
US (1) US20220296544A1 (es)
EP (1) EP4023219A4 (es)
CN (1) CN114450001A (es)
BR (1) BR112022002176A2 (es)
CA (1) CA3147206A1 (es)
CO (1) CO2022002493A2 (es)
MX (1) MX2019009482A (es)
WO (1) WO2021025550A1 (es)
ZA (1) ZA202202125B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159476A1 (en) 2022-02-25 2023-08-31 L'oreal Composition for caring for keratin materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2072014B (en) * 1980-03-08 1984-02-15 Kanebo Ltd Cosmetics containing 18-glycyrrhizins
LU86396A1 (fr) * 1986-04-18 1986-09-02 Pharma Roche Posay Lab Compositions pour le traitement de la calvitie et des alopecies
MX351117B (es) * 2011-02-25 2017-10-03 Desarrollos Vph S A De C V Formulacion de la sal acido glicirricinico en gel termorreversible y acido tricloroacetico para su aplicacion en el tracto genital de mujeres y varones con lesiones causadas por el virus del papiloma humano y cancer en los mismos.
RU2493852C1 (ru) * 2012-04-12 2013-09-27 Леонид Леонидович Клопотенко Композиция, содержащая фермент дезоксирибонуклеазу и/или стеарилглицирретинат или глицирризиновую кислоту или ее соли: глицирризинат аммония, или дикалия, или тринатрия
CN105342987A (zh) * 2015-12-04 2016-02-24 亚飞（上海）生物医药科技有限公司 一种凝胶及其制备方法和应用
ITUB20159218A1 (it) * 2015-12-21 2017-06-21 Valitudo Pharma Srls Composizione, per uso topico, utile per favorire la cicatrizzazione di lesioni sulla pelle.
MX2017010806A (es) * 2017-08-22 2018-01-18 Atso Corp Affairs S A De C V Formulacion de acido 18-beta-glicirretinico en combinacion con revesterol y metformina, usos y metodo de fabricacion.

Also Published As

Publication number Publication date
EP4023219A1 (en) 2022-07-06
CA3147206A1 (en) 2021-02-11
WO2021025550A1 (es) 2021-02-11
BR112022002176A2 (pt) 2022-05-03
CN114450001A (zh) 2022-05-06
MX2019009482A (es) 2021-02-09
US20220296544A1 (en) 2022-09-22
ZA202202125B (en) 2023-11-29
EP4023219A4 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
DOP2016000316A (es) Dinucleótidos cíclicos como moduladores de sting
NZ727975A (en) Compositions comprising electrohydrodynamically obtained fibres for administration of specific dosages of an active substance to skin or mucosa
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
BRPI0924460A2 (pt) composição farmacêutica para uso em oftalmologia médica e veterinária
BR112014023379A8 (pt) Microemulsões com base em ciclodextrina e usos dermatológicos das mesmas
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EA201890643A1 (ru) Лекарственные средства и медицинские изделия, содержащие ацетилсалициловую кислоту для лечения кожных инфекций, вызванных вирусом папилломы человека
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
CL2018003682A1 (es) Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos.
CO2022002493A2 (es) Nanoemulsion de ácido 18p-glicirretínico
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
CY1113885T1 (el) Μια ιατρικη κρεμα φουσιδικου οξεος που παρασκευαζεται με την χρηση φουσιδικου νατριου και ενσωματωση ενος βιοπολυμερους και μια μεθοδος για την παρασκευη της
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
ECSP22092205A (es) Composición farmacéutica acuosa de levilimab y su uso
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
BR112018067353A2 (pt) composição farmacêutica e uso de um composto ativo para tratar uma doença causada por vírus do gênero flavivirus em um feto de mamífero
BR112022010340A2 (pt) Composições farmacêuticas
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
CO2020002287A2 (es) Composiciones farmacéuticas
AR117298A1 (es) Aglutinante de péptido
CO2021014253A2 (es) Formulación de tableta vaginal
UA123399U (uk) Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування